Credit Suisse Ag Seres Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$2.33 - $5.07 $77,835 - $169,368	-33,406 Reduced 19.56%	137,376 $326,000
Q2 2023 Aug 11, 2023	BUY	$4.67 - $6.55 $224,122 - $314,347	47,992 Added 39.08%	170,782 $818,000
Q1 2023 May 10, 2023	BUY	$4.95 - $6.09 $133 - $164	27 Added 0.02%	122,790 $696,000
Q4 2022 Feb 13, 2023	BUY	$5.09 - $9.05 $31,272 - $55,603	6,144 Added 5.27%	122,763 $687,000
Q3 2022 Nov 10, 2022	BUY	$3.5 - $7.2 $91,910 - $189,072	26,260 Added 29.06%	116,619 $749,000
Q2 2022 Aug 12, 2022	BUY	$2.7 - $7.62 $9,536 - $26,913	3,532 Added 4.07%	90,359 $309,000
Q1 2022 May 16, 2022	BUY	$6.3 - $8.84 $23,776 - $33,362	3,774 Added 4.54%	86,827 $618,000
Q4 2021 Feb 14, 2022	BUY	$6.02 - $11.43 $220,325 - $418,326	36,599 Added 78.79%	83,053 $692,000
Q3 2021 Nov 12, 2021	BUY	$5.46 - $22.6 $19,896 - $82,354	3,644 Added 8.51%	46,454 $323,000
Q2 2021 Aug 16, 2021	SELL	$18.46 - $24.36 $94,201 - $124,309	-5,103 Reduced 10.65%	42,810 $1.02 Million
Q1 2021 May 14, 2021	SELL	$17.66 - $28.92 $1.21 Million - $1.98 Million	-68,605 Reduced 58.88%	47,913 $987,000
Q4 2020 Feb 12, 2021	BUY	$23.25 - $37.73 $2.71 Million - $4.4 Million	116,518 New	116,518 $2.85 Million
Q2 2018 Aug 14, 2018	SELL	$6.91 - $9.55 $97,285 - $134,454	-14,079 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$7.34 - $11.16 $26,394 - $40,131	3,596 Added 34.3%	14,079 $103,000
Q4 2017 Feb 14, 2018	SELL	$9.15 - $12.64 $95,013 - $131,253	-10,384 Reduced 49.76%	10,483 $106,000
Q3 2017 Nov 14, 2017	BUY	$12.81 - $16.85 $123,155 - $161,995	9,614 Added 85.43%	20,867 $334,000
Q2 2017 Aug 14, 2017	BUY	N/A	11,253	11,253 $127,000

Others Institutions Holding MCRB

# of Institutions

Shares Held

39.4M

Call Options Held

103K

Put Options Held

53K

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $906M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account